Tags

Type your tag names separated by a space and hit enter

A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10.
Int J Tissue React 1990; 12(3):169-71IJ

Abstract

One hundred and forty-three cases of chronic, stable, non-secondary, non-hypertrophic cardiomyopathy, 98% of whom were in NYHA Classes III and IV, were given 100 mg of coenzyme Q10 orally in addition to their conventional medical programme in an open-label long-term study. Blood CoQ10 levels, clinical status, myocardial function and survival have been recorded now for almost 6 years. Mean control/CoQ10 levels of 0.85 micrograms/ml rose to 2 micrograms/ml in 3 months and remained stable at that level. Mean ejection fraction of 44% measured by systolic time interval analysis rose to 60% within 6 months and stabilized at that level with 84% of patients showing statistically significant improvement. Eighty-five percent of patients improved by one or two NYHA Classes. Survival figures were encouraging with an 11.1% mortality in 12 months and 17.8% mortality in 24 months, comparing favourably with several reports in the literature. There was no positive evidence of toxicity or intolerance in a total of 368.9 patient-years of exposure. Coenzyme Q10 is safe and effective long-term therapy for chronic cardiomyopathy.

Authors+Show Affiliations

Department of Medicine, Scott & White Clinic, Temple, TX.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2276895

Citation

Langsjoen, P H., et al. "A Six-year Clinical Study of Therapy of Cardiomyopathy With Coenzyme Q10." International Journal of Tissue Reactions, vol. 12, no. 3, 1990, pp. 169-71.
Langsjoen PH, Langsjoen PH, Folkers K. A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10. Int J Tissue React. 1990;12(3):169-71.
Langsjoen, P. H., Langsjoen, P. H., & Folkers, K. (1990). A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10. International Journal of Tissue Reactions, 12(3), pp. 169-71.
Langsjoen PH, Langsjoen PH, Folkers K. A Six-year Clinical Study of Therapy of Cardiomyopathy With Coenzyme Q10. Int J Tissue React. 1990;12(3):169-71. PubMed PMID: 2276895.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10. AU - Langsjoen,P H, AU - Langsjoen,P H, AU - Folkers,K, PY - 1990/1/1/pubmed PY - 1990/1/1/medline PY - 1990/1/1/entrez SP - 169 EP - 71 JF - International journal of tissue reactions JO - Int J Tissue React VL - 12 IS - 3 N2 - One hundred and forty-three cases of chronic, stable, non-secondary, non-hypertrophic cardiomyopathy, 98% of whom were in NYHA Classes III and IV, were given 100 mg of coenzyme Q10 orally in addition to their conventional medical programme in an open-label long-term study. Blood CoQ10 levels, clinical status, myocardial function and survival have been recorded now for almost 6 years. Mean control/CoQ10 levels of 0.85 micrograms/ml rose to 2 micrograms/ml in 3 months and remained stable at that level. Mean ejection fraction of 44% measured by systolic time interval analysis rose to 60% within 6 months and stabilized at that level with 84% of patients showing statistically significant improvement. Eighty-five percent of patients improved by one or two NYHA Classes. Survival figures were encouraging with an 11.1% mortality in 12 months and 17.8% mortality in 24 months, comparing favourably with several reports in the literature. There was no positive evidence of toxicity or intolerance in a total of 368.9 patient-years of exposure. Coenzyme Q10 is safe and effective long-term therapy for chronic cardiomyopathy. SN - 0250-0868 UR - https://www.unboundmedicine.com/medline/citation/2276895/A_six_year_clinical_study_of_therapy_of_cardiomyopathy_with_coenzyme_Q10_ L2 - http://www.diseaseinfosearch.org/result/1090 DB - PRIME DP - Unbound Medicine ER -